Heraldnet.com
SUNDAY, JULY 5, 2009 2:07 pm
LocalNorthwestNation & WorldPoliticsSpecial ReportsPhotosColumnistsMultimedia 
Blog
Michelle Dunlop
Tests continue on Boeing's 787
Your town news
Mike Benbow
Business editor Mike Benbow's insights into all things business.
•Latest: State's new commerce director shares his business principles
Steve Tytler
Steve Tytler answers your questions about real estate.
•Latest: Landlords should read up before they rent out
 
WEEK IN REVIEW
Saturday


Fireworks blamed in Marysville house fire
Sailors for a day: Naval Station Everett opens ...
Edmonds backs off red-light cameras
Friday
Armed man shot by deputies in Arlington
Police ID make of vehicle in fatal hit-and-run
Boeing's 6-month tally: 1 net order
Thursday


One fire rips through $2 million home, another ...
Swine flu claims 2nd victim in Snohomish County
Jetty Island firefight continues; hot weather ...
Wednesday


Fire District 1 negotiates to take over service...
Snohomish County population rising fast since 2...
Honey's owners indicted by feds
Tuesday


Mobile home tenants along Snohomish River told ...
Lincoln to leave Everett in 2013
Put on your sailor's cap and explore Naval Stat...
Monday


Disabled people will be left without a ride
You'll soon have 4,500 reasons to trade in that...
Pay hike deserved, Monroe chief says
Sunday


1,670 local students in county are without homes
Monroe's business gets done in secret
$9 million to be sought for U.S. 2 in federal t...
 

ADVERTISEMENT

Business   Print This Article  Email This Page  Subscribe Now! facebook digg reddit del.icio.us fark stumble

 
ADVERTISEMENT

 
CONTACT THE HERALD
Mike Benbow, Business Editor
benbow@heraldnet.com
 
Published: Tuesday, August 5, 2008

Biotech firm cuts president, 22 other jobs

Bothell-based MDRNA Inc. cut nearly 150 jobs since fall as it tries to reinvent itself.

BOTHELL -- MDRNA Inc. is laying off 23 more employees, including its president, as the biotechnology firm formerly known as Nastech Pharmaceuticals tries to reinvent itself.

After the job cuts, which are effective immediately, Bothell-based MDRNA will employ 55 people full time by the end of this month. Since last fall, MDRNA has slashed nearly 150 positions.

In the second quarter, the company lost more than $14 million, or 48 cents a share, up from a loss of $12 million in the year-ago period. The company's revenue totaled $700,000, down sharply from nearly $5 million in the same quarter of 2007.

MDRNA, which ended the second quarter with just less than $20 million in cash and short-term investments, will take a nearly $2 million charge to cover severance and other costs related to the layoffs.

Once focused on nasally inhaled medications, MDRNA shifted its name and focus after a series of setbacks in its drug development programs. The biggest blow was Procter & Gamble Pharmaceuticals' termination of an agreement to help the company develop a nasal spray to treat osteoporosis. The drug development agreement potentially was worth more than $500 million.

In the months since losing that agreement, MDRNA's shares have lost more than 90 percent of their value.

That tailspin resulted in the company's decision to turn its research focus from nasally inhaled drugs to RNA interference, a cellular mechanism that can halt proteins vital to expanding viruses in the body. The company hopes it can use RNA interference to develop treatments for a variety of cancers and other conditions.

That new focus, the company's new name and other changes were announced in early June. Michael French, who took over as chief executive officer at that time, said the transition continues. With that in mind, most of the 23 people being laid off are from the company's nasal development programs. Also included are the company's president, Gordon Brandt; its chief business officer; and the chief scientific officer in charge of nasal delivery programs.

French said MDRNA will not start any new research on nasally inhaled medications. Instead, 60 percent of the remaining work force will be focused on research and development related to RNA interference, he said. By 2010, the company may be ready to begin clinical trials on such new drugs.

The company still hopes, however, to recoup some of its years of work and investment into nasally delivered drugs, Brandt said.

"We believe that our intranasal assets have significant value," Brandt said, adding that MDRNA has received several inquiries from firms interested in acquiring those drug development programs. "We hope to be able to announce one or more such transactions soon."



Reporter Eric Fetters: 425-339-3453 or fetters@heraldnet.com.

1. Waves wash away Explosion's title hopes
2. You've got your pick of Fourth of July fun
3. Snohomish entrepreneur bounces back with new venture
4. Inslee downplays fears Boeing will send second 787 line elsewhere
5. Popular park changing hands
6. Deputies shoot armed man near Arlington
7. Why, governor?
8. Edmonds backs off red-light cameras
9. Vehicle that killed girl was Chevy Astro minivan
10. Arlington buys up more water rights
Enterprise Newspaper Snohomish County Business Journal
Warriors looking for balance
Three Scots vying for QB slot
Jackson looks for another title
Decorated veteran continues to serve as active volunteer
City Council reviewing sign regulations
Wildcats get a peek at newcomers
Lynnwood still in rebuilding mode
Shoreline feels a kindergarten growth spurt
Leave the patriotic pyrotechnics to professionals, cities urge
The Enterprise Online Newspaper

TODAY'S TOP JOBS
 View All Top Jobs 
Top Cars
Top Homes


ADVERTISEMENT